Published online Jun 14, 2024. doi: 10.3748/wjg.v30.i22.2843
Revised: May 10, 2024
Accepted: May 20, 2024
Published online: June 14, 2024
Processing time: 68 Days and 22.9 Hours
Hepatocellular carcinoma (HCC) is the most common and deadliest subtype of liver cancer worldwide and, therefore, poses an enormous threat to global health. Understanding the molecular mechanisms underlying the development and progression of HCC is central to improving our clinical approaches. PIWI-interacting RNAs (piRNAs) are a class of small non-coding RNAs that bind to PIWI family proteins to regulate gene expression at transcriptional and post-transcriptional levels. A growing body of work shows that the dysregulation of piRNAs plays a crucial role in the progression of various human cancers. In this editorial, we report on the current knowledge of HCC-associated piRNAs and their potential clinical utility. Based on the editorial by Papadopoulos and Trifylli, on the role and clinical evaluation of exosomal circular RNAs in HCC, we highlight this other emerging class of non-coding RNAs.
Core Tip: Hepatocellular carcinoma (HCC) is a worldwide clinical problem. Over the past decade, several papers have suggested that specific PIWI-interacting RNAs (piRNAs) may be useful as efficient HCC biomarkers at both tissue and serum levels. Interestingly, the piRNA expression profile changes dynamically over the course of the pathological stage from liver fibrosis to HCC development and progression. Knowledge of piRNAs may improve our understanding of HCC and open new clinical perspectives.